Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma industry interest in NICE/MHRA parallel advice still limited but UK early access scheme 'could foster use'

This article was originally published in SRA

Executive Summary

Demand by drug companies for the parallel scientific advice scheme that UK health technology assessment body NICE has in place with the Medicines and Healthcare Products Regulatory Agency has been extremely limited to date. Nonetheless, NICE considers the joint advice "a good opportunity for a detailed engagement on both regulatory and HTA issues and evidence requirements" and says there could be added interest soon.

You may also be interested in...



COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs And Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

EMA Issues Guidance On Compassionate Use Of Remdesivir For COVID-19

Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.

UsernamePublicRestriction

Register

PS118264

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel